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Abstract 
The headroom method was introduced for the very early evaluation of the potential value of new technologies. It 
allows for establishing a ceiling price for technologies to still be cost-effective by combining the maximum 
effect a technology might yield, the maximum willingness-to-pay (WTP) for this effect, and potential 
downstream expenses and savings. Although the headroom method is QALY-based, not all innovations are 
expected to result in QALY gain. This paper explores the feasibility and usefulness of the headroom method in 
the evaluation of technologies that are unlikely to result in QALY gain. This will be illustrated with the 
diagnostic trajectory of complex paediatric neurology (CPN).   
Our headroom analysis showed a large room for improvement in the current diagnostic trajectory of CPN in 
terms of diagnostic yield. Combining this with a maximum WTP value for an additional diagnosis and the 
potential downstream expenses and savings, resulted in a total headroom of €14,088. This indicates that a new 
technology in this particular diagnostic trajectory, might be cost-effective as long as its costs do not exceed 
€14,088. 
The headroom method seems a useful tool in the very early evaluation of medical technologies, also in cases 
when an immediate QALY gain is unlikely. It allows for allocating health care resources to those technologies 
that are most promising. It should be kept in mind however, that the headroom assumes an optimistic scenario, 
and for that reason cannot guarantee future cost-effectiveness. It might be most useful for ruling out those 
technologies that are unlikely to be cost-effective.  
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Introduction 
Technological innovations are known to be a major cost driver in healthcare[1]. Since healthcare expenditures 
are rapidly increasing and economic pressure is also expanding, there is growing need for early evaluation of the 
potential value of such innovations.  
The health economic evaluation process alongside the development of new technologies can roughly be divided 
into three phases[2, 3]. In the very early phase, a technology is still in concept, and not yet under development. 
Generally, decisions on product development have to be made with no, or only limited evidence on costs and 
effectiveness being available. Once a positive development decision has been made, a technology enters the 
development stage. Some clinical evidence on costs and effectiveness becomes available, allowing for early 
stage evaluation such as iterative decision modelling and one-way sensitivity analyses for determining the key 
parameters influencing the technology’s cost-effectiveness[4].  
Health economic evaluations including cost-effectiveness, cost-utility, and value-of-information analyses are 
mostly performed at a late stage of development. At this post market stage, a technology has already been 
developed and brought to market, and additional costs and effectiveness data are becoming available from 
clinical studies. If, at this stage, a technology appears not to be cost-effective, it might not be reimbursed. In this 
case, considerable investments in research and development have been made that cannot be recovered.  To 
predict these wasted resources, there is interest in making reliable estimates of the cost-effectiveness of 
innovations at an early stage of development. 
As a tool to select those technologies that are most likely to provide value for money from a large pool of ideas, 
Cosh et al. introduced the headroom method[5]. This method examines the potential of a new technology under 
optimistic assumptions. It aims to quantify the room for improvement in current clinical practice by combining 
the maximum effect an innovation might have, the maximum willingness to pay (WTP) for this effect, and the 
potential downstream expenses and savings. Thus, the headroom method is an assessment of the maximum 
potential value of an innovation, informing on the upper ceiling price of a technology, to still be cost-
effective[5]. If it is realistic to assume that the headroom is large enough to cover the costs of the new 
technology, further development and economic analyses are worth undertaking. If the headroom is too low, on 
the other hand, one might rather focus on other innovations.  
The headroom method was introduced and is currently used on a quality-adjusted life year (QALY) basis[5-7]. 
This implies that effectiveness is measured in terms of QALYs, which are a combined measure of health-related 
quality of life and life years gained from an intervention[8]. However, not every innovation is expected to result 
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in QALY gain. This is for example the case in technologies that are expected to increase diagnostic yield or 
expedite diagnosis in untreatable diseases. As these technologies are not expected to result in QALY gain, 
performing a headroom analysis on a QALY basis would result in direct rejection, even though such a 
technology might improve clinical practice in other ways and therefore be valuable.  
Such a scenario arises in the diagnostic trajectory of complex paediatric neurology. Complex paediatric 
neurologic disorders are a heterogeneous group of predominantly genetic disorders including epilepsy, 
movement disorders, neuromuscular disorders and metabolic disorders. The current diagnostic trajectory for 
these patients is lengthy, resource-intensive and has a low diagnostic yield[9]. Therefore, it is expected that there 
is ample room for improvement in this diagnostic trajectory, especially in terms of diagnostic yield and duration. 
As effective treatments for these disorders are currently often not available, no QALY gain as a result of 
improving this trajectory may be expected.  
This paper explores the feasibility and usefulness of the headroom method in the very early health economic 
evaluation of diagnostic technologies that are not expected to result in a QALY gain. The first part of the paper 
will describe the theory behind the headroom method. In the second part of the paper, the case of the diagnostic 
trajectory in complex paediatric neurology will be used as an illustration on the feasibility and usefulness of the 
headroom method for technologies that are not expected to result in an immediate QALY gain.  
 
The headroom method 
The headroom method is based on the net-monetary-benefit equation as introduced by Hoch et al.[10]. It 
involves two main aspects, namely the establishment of what is called the 'effectiveness gap', and the actual 
calculation of the headroom, which is the maximum additional cost at which the implementation of a new 
technology could still be considered cost-effective[11]. As we are interested in an upper ceiling price for a new 
technology, this calculation assumes an optimistic scenario, taking into account the maximum effect a new 
technology might yield (effectiveness gap), society’s WTP for this incremental effect and any costs or savings 
associated with use of the new technology. This results in equation 1, of which each step will be further 
explained in the following paragraphs.  
 
  (1) 
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The effectiveness gap 
New diagnostic technologies are being developed because they are expected to be more effective than current 
clinical practice. For an innovation to be more effective, there needs to be room for improvement in current 
practice. This room for improvement is the maximum increase in effectiveness a new technology could provide 
compared to the reference standard, also defined as the effectiveness gap[5]. This is represented by equation 2, in 
which max effectnt is the maximum effect the new technology could provide compared to current clinical practice 
(effectcp). 
 
  (2) 
 
There are several measures to express this effectiveness gap, such as life years gained, number of diagnoses, or 
unnecessary diagnostic tests prevented. However, the preferred outcome measure is the QALY, which combines 
health-related quality of life and survival.  
For example, McAteer et al. assumed that the use of bowel tissue in substitution cystoplasty, which is the 
reference standard, after resection for bladder cancer, resulted in a median utility score of 0.95. They compared 
this technique to tissue-engineered bladder substitute, which has a maximum increment in effect of 1 – 0.95 = 
0.05. Assuming that bladder cancer patients live for 10 more years after resection, the effectiveness gap in this 
case would be (1– 0.95) x 10 = 0.5 QALY[12]. 
 
Headroom calculation 
As in net-monetary-benefit calculation, the effectiveness gap should be valued in monetary terms. This is done 
by multiplying the effectiveness gap with a certain maximum willingness-to-pay value for an additional unit of 
effect. For QALYs, such a willingness-to-pay value is in the UK well established between £20,000 and £30,000 
for every additional QALY gained[13]. This means that, according to equation 1, in the example of McAteer et 
al., the headroom for tissue-engineered bladder substitute equals 0.5 * 30,000 = 15,000[12].  
Additionally, the introduction of a new technology might be accompanied with potential downstream expenses 
or savings, indirect costs such as productivity losses, or wider infrastructural costs such as staff training, which 
should also be taken into account in a total headroom calculation[14]. For example, McAteer et al. considered a 
potential saving in hospital bed days as a consequence of tissue engineering compared to current clinical 
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practice[12]. They found a mean saving of four hospital days with an average cost of £317 per day. Hence, in 
their case, an additional saving of £1,268 could be added to the total headroom. 
 
The headroom of the diagnostic trajectory in complex paediatric neurology 
In this part of the paper we will illustrate the feasibility and the usefulness of the headroom method in the 
diagnostic trajectory of complex paediatric neurology. First we will define the effectiveness gap of the current 
diagnostic trajectory. Second we will calculate the headroom, given a certain willingness-to-pay value and taking 
into account additional savings and expenses. 
 
Assessing the effectiveness gap of the current diagnostic trajectory 
Complex paediatric neurologic disorders are a heterogeneous group of predominantly genetic disorders and 
patients present at the neurologist with non-specific symptoms. Although these patients clearly have a neurologic 
disorder, their diagnostic trajectories are generally long-term and a clinical diagnosis is established in only a 
small minority. Despite complex paediatric neurologic disorders being generally untreatable, a definitive 
diagnosis might end the diagnostic Odyssey and provide useful information on disease aetiology, prognosis, and 
/ or family planning.  
Currently, the diagnostic trajectories of these patients take on average 40 months, include extensive imaging, 
neurophysiologic, and genetic testing, and result in a definitive diagnosis for only 6% of the patients[9]. These 
numbers suggest ample room for improvement in this diagnostic trajectory. In the most optimistic scenario, only 
two physician visits and one diagnostic test are required to provide a definitive diagnosis for every patient. This 
could reduce the length of the diagnostic trajectory considerably, while increasing diagnostic yield from 6% to 
100%. This results in an effectiveness gap of 94% or 0.94. Note that we are not assuming that in reality a new 
technology will close all of the effectiveness gap. The effectiveness gap here is the maximum effect that could be 
achieved hypothetically, informing on an upper ceiling price for a new technology to be still cost-effective. In 
this way, we assume the most optimistic scenario, with the new technology being a perfect test, providing a 
diagnosis for all patients without false positive or false negative results.  
 
Monetising the effectiveness gap 
To monetise the effectiveness gap we need to know the monetary value for an additional unit of benefit. 
Although for QALYs the willingness-to-pay is well established between £20,000 and £30,000, for intermediate 
outcomes willingness-to-pay values are less clear. Regier et al. studied families of children with idiopathic 
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developmental disability, in which the exact cause of the disability was unknown[15]. Using a discrete choice 
experiment, they simultaneously obtained monetary values for increasing the diagnostic yield, and for reducing 
the interval between presentation and diagnosis. They presented test scenarios with varying levels of diagnostic 
yield (10, 14, 20, and 25 out of 100 children tested); time waiting for results (1, 3, 6, and 12 weeks); and cost to 
the family (CND$750, CND$1100, CND$1750, and CND$2500). They found that families of patients were 
willing to pay approximately €85 (CND$131) for one additional child receiving a diagnosis in every 100 patients 
tested. This implies a WTP of €85 per percentage point additional diagnostic yield. As mentioned before, in the 
most optimistic scenario, the diagnostic yield in complex paediatric neurology will increase from 6% to 100%, 
resulting in an effectiveness gap of 94%. Assuming that the WTP value of €85 found by Regier et al. is a 
representative value for the societal WTP for one extra diagnosis in every 100 patients in paediatric neurology, 
the monetised effectiveness gap in current practice would be 94 x €87 = €7,990. 
 
Net additional costs  
Implementing new technologies into clinical practice might result in additional expenses or savings. As the 
majority of complex paediatric neurologic disorders have a genetic origin, it is likely that innovations in this 
diagnostic pathway are in the field of next-generation sequencing (NGS). Applying these technologies in clinical 
practice may lead to so-called incidental findings, which are clinically relevant mutations that are not related to 
the disease under investigation[16]. These might lead to follow-on testing and treatment initiation - potentially 
with complications - and thereby cause downstream expenses. Although these incidental findings are very rare, 
their downstream costs can be considerable[14]. In contrast, the application of NGS early in the diagnostic 
trajectory might partly substitute current diagnostic testing, especially genetic tests.  
For this headroom analysis we assume an optimistic scenario, consistent with its underlying philosophy, which is 
to determine an upper ceiling price to be still cost-effective in such a scenario. To this end, we assume that there 
are no downstream costs, as incidental findings are very rare. Moreover, NGS is assumed to substitute all 
genetics tests of the current diagnostic trajectory, as well as 25% of all physician contacts. These substitutions 
would result in savings equalling €6,098 per patient[9]. 
 
Interpreting the headroom 
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When ignoring additional costs or savings, the headroom in the current diagnostic trajectory of complex 
paediatric neurology equals €7,990. This means that if a new technology would be introduced as an add-on test, 
the maximal marginal cost would be €7,990.  
Taking into account the expected savings of €6,098 by substituting all genetic tests and 25% of the physician 
visits, the total headroom equals €7,990 + €6,098 = €14,088. Of course, there is uncertainty around the number 
of current diagnostics that will be replaced by a new technology. To address this uncertainty, additional scenario 
analyses regarding these substitution savings can be performed to reduce the chance of investing in a technology 
that at a later stage turns out not to be cost-effective. Figure 1 shows the total headroom in the diagnostic 
trajectory of complex paediatric neurology in the case of an add-on test and in a scenario in which the new 
technology partly substitutes current diagnostics.  
 
Discussion 
This paper shows that headroom analysis is a feasible and useful tool in the early health economic evaluation of 
diagnostic technologies, also when no immediate QALY gain is expected. An effectiveness gap calculation is 
informative on the room for improvement in current clinical practice. It indicates whether there is a problem, and 
allows for quantification of this problem. Additionally, combining a monetary valuation of the effectiveness gap 
with the foreseeable downstream costs and savings due to a new technology provides an estimation of the 
potential societal value of this technology. In the case of complex paediatric neurology, headroom analysis 
indicated a large room for improvement, as in the current trajectory only 6% of all patients receive a diagnosis. 
In addition, it is realistic to assume that savings will materialize since new technologies can substitute a 
considerable part of the current diagnostic trajectory. A total headroom of €14,088 was found, indicating that a 
new technology in this diagnostic trajectory could be cost-effective if its costs do not exceed €14,088.  
Although definitely informative, it should be noted that the headroom method has certain limitations. Most 
notably, the headroom method assumes an optimistic scenario, with the effectiveness gap considering the 
maximum effect a new technology might theoretically gain. However, in clinical practice, new technologies are 
unlikely to be perfect and will therefore not close the entire effectiveness gap. Therefore, the established ceiling 
price is likely to be an overestimation, and it cannot be guaranteed that a technology that is brought to the market 
for less than this ceiling price will actually be cost-effective. On the other hand, Chapman et al. show that with a 
specificity of 92%, the headroom method is a very valuable tool in no-go decisions, to avoid investment in 
technologies that could never be cost-effective, as its expected costs exceed the calculated headroom[17]. 
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Clearly, one could also calculate the effectiveness gap with a range of more realistic estimates of effectiveness in 
a scenario analysis on the effectiveness. Finally, updating the initial headroom analysis when more evidence 
becomes available, gives more accurate estimations on the potential value of a technology and thereby reduces 
chances on investing in technologies that are unlikely to meet societal criteria of cost-effectiveness[18].  
The same goes for downstream costs and additional expenses and savings. In early stages, these are highly 
uncertain. It is hard to decide to what extent and over what time these costs and savings should be taken into 
account, and to what extent these will vary within and between countries. Here too, scenario analyses can 
provide insight in the expected value of a new technology. 
Finally, intermediate outcomes are difficult to value in monetary terms, complicating headroom analyses of 
technologies that do not result in QALY gain. This difficulty in monetising value beyond the QALY, such as 
family planning or wellbeing, equally complicates economic evaluations that attempt to quantify the actual value 
of such innovations, however[19]. Although for QALYs a clear WTP threshold has been established, this is often 
not the case for intermediate outcomes. Determining the WTP for intermediate outcomes can be done by using, 
for example, contingent valuation or discrete choice experiments. However, these are relatively time-consuming 
and expensive methods to conduct, especially in such an early stage of evaluation. Moreover, as intermediate 
outcomes may be valued differently in varying disease areas, WTP values should be determined for specific 
diseases [20]. 
Despite these limitations, the headroom method seems a useful tool. For the supply side, it does not only inform 
on the commercial opportunity of a technology by establishing a maximum ceiling price for which it could be 
cost-effectively brought to market. It is also a quick method for rapid decision-making in both selecting the most 
promising concepts from a larger pool of options, and in investment and development decisions[3]. Especially 
when combined with some additional scenario analyses on both costs and effectiveness parameters, it could be 
helpful in channelling research and development resources towards those technologies that are most promising.  
 
Conclusion 
The headroom seems a valuable tool in the very early evaluation of medical technologies, even when no 
immediate gain in QALYs is expected. It is informative on the room for improvement in a certain disease area 
and allows for selecting the most promising concepts from a larger pool of options, for decision-making 
regarding investments in research and further development, and for calculating a maximum ceiling price to still 
be-cost effective. As an optimistic scenario is assumed, it indicates the potential for, but does not guarantee 
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future cost-effectiveness and / or reimbursement. Hence, the headroom method might be most valuable as a rule-
out tool to avoid investment in technologies that are very unlikely to be able to meet even the most generous 
criteria for  cost-effectiveness. 
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